Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 16.38% is 140% above its 5-year average of 6.83%, near the high end of its 5-year range (0.18%–16.38%).
As of the fiscal period ended Wednesday, December 31, 2025. 115.10% above its 12-month average of 7.62%.
Annual fiscal-year return on assets; no daily interpolation.
RETURN ON ASSETS (ROA)
16.38%
RETURN ON ASSETS (ROA) AVG TTM
7.62%
RETURN ON ASSETS (ROA) AVG 3Y
7.90%
RETURN ON ASSETS (ROA) AVG 5Y
6.83%
RETURN ON ASSETS (ROA) AVG 10Y
11.23%
RETURN ON ASSETS (ROA) AVG 15Y
11.11%
RETURN ON ASSETS (ROA) AVG 20Y
16.53%
CURRENT VS TTM AVG
+115.10%
CURRENT VS 3Y AVG
+107.21%
CURRENT VS 5Y AVG
+139.94%
CURRENT VS 10Y AVG
+45.82%
CURRENT VS 15Y AVG
+47.38%
CURRENT VS 20Y AVG
-0.88%
SECTOR MEDIAN · HEALTHCARE
4.97%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
+229.58%
vs the sector median at left
Gilead Sciences, Inc.
Market Cap
$161.66B
Return on Assets (ROA)
16.38%
TTM Avg
7.62%
3Y Avg
7.90%
5Y Avg
6.83%
Market Cap
$142.54B
Return on Assets (ROA)
3.61%
TTM Avg
3.75%
3Y Avg
6.08%
5Y Avg
7.08%
Market Cap
$182.90B
Return on Assets (ROA)
4.97%
TTM Avg
11.99%
3Y Avg
10.28%
5Y Avg
9.45%
Market Cap
$137.13B
Return on Assets (ROA)
4.33%
TTM Avg
4.68%
3Y Avg
5.89%
5Y Avg
6.01%
Market Cap
$133.41B
Return on Assets (ROA)
10.59%
TTM Avg
-0.92%
3Y Avg
3.28%
5Y Avg
1.99%
Market Cap
$133.25B
Return on Assets (ROA)
1.16%
TTM Avg
1.25%
3Y Avg
1.93%
5Y Avg
2.38%
Market Cap
$131.47B
Return on Assets (ROA)
9.11%
TTM Avg
7.88%
3Y Avg
6.26%
5Y Avg
4.99%
Market Cap
$124.86B
Return on Assets (ROA)
7.78%
TTM Avg
6.88%
3Y Avg
7.02%
5Y Avg
6.41%
Market Cap
$124.82B
Return on Assets (ROA)
15.04%
TTM Avg
13.09%
3Y Avg
12.00%
5Y Avg
11.68%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. (GILD) | $161.66B | 16.38% | 7.62% | 7.90% | 6.83% |
| Pfizer Inc. (PFE)vs › | $142.54B | 3.61% | 3.75% | 6.08% | 7.08% |
| Abbott Laboratories (ABT)vs › | $182.90B | 4.97% | 11.99% | 10.28% | 9.45% |
| Danaher Corporation (DHR)vs › | $137.13B | 4.33% | 4.68% | 5.89% | 6.01% |
| Bristol-Myers Squibb Company (BMY)vs › | $133.41B | 10.59% | -0.92% | 3.28% | 1.99% |
| CVS Health Corp. (CVS)vs › | $133.25B | 1.16% | 1.25% | 1.93% | 2.38% |
| AstraZeneca PLC (AZN)vs › | $131.47B | 9.11% | 7.88% | 6.26% | 4.99% |
| Stryker Corporation (SYK)vs › | $124.86B | 7.78% | 6.88% | 7.02% | 6.41% |
| Intuitive Surgical, Inc. (ISRG)vs › | $124.82B | 15.04% | 13.09% | 12.00% | 11.68% |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $121.09B | 16.38% | 6.37% | 11.74% | 14.58% |
ROA
16.4%
ROE
39.2%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 14.42% |
| 2024-12-31 | 0.81% |
| 2023-12-31 | 9.12% |
| 2022-12-31 | 7.27% |
| 2021-12-31 | 9.16% |
| 2020-12-31 | 0.18% |
| 2019-12-31 | 8.74% |
| 2018-12-31 | 8.57% |
| 2017-12-31 | 6.58% |
| 2016-12-31 | 23.70% |
| 2015-12-31 | 35.01% |
| 2014-12-31 | 34.91% |
| 2013-12-31 | 13.62% |
| 2012-12-31 | 12.20% |
| 2011-12-31 | 16.20% |
| 2010-12-31 | 25.03% |
| 2009-12-31 | 27.18% |
| 2008-12-31 | 28.53% |
| 2007-12-31 | 27.68% |
| 2006-12-31 | -29.12% |
| 2005-12-31 | 21.61% |
| 2004-12-31 | 20.84% |
| 2003-12-31 | -4.63% |
| 2002-12-31 | 5.60% |
| 2001-12-31 | 6.58% |
| 2000-12-31 | -8.37% |
| 1999-12-31 | -15.22% |
| 1998-12-31 | -9.18% |
| 1997-12-31 | -20.70% |
| 1996-12-31 | -6.98% |
